Hartmann Tanja N, Pleyer Lisa, Desch Petra, Egle Alexander, Greil Richard
Laboratory for Immunological and Molecular Cancer Research, IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg 5020, Austria.
Discov Med. 2009 Oct;8(42):157-64.
Chronic lymphocytic leukemia (CLL) is a malignancy mainly affecting elderly people and is still considered an incurable disease. Despite recent advances in CLL treatment, relapse rates are high and often accompanied by the development of resistance towards conventional chemotherapy. Thus, new agents are needed for the treatment of these patients. In recent years, our understanding of the biological mechanisms driving CLL pathogenesis has considerably improved, and novel treatment strategies are arising. This review summarizes recent insights in CLL biology and describes several new agents and treatment strategies that are currently explored in pre-clinical studies and early-phase clinical trials.
慢性淋巴细胞白血病（CLL）是一种主要影响老年人的恶性肿瘤，目前仍被认为是一种无法治愈的疾病。尽管近年来CLL治疗取得了进展，但复发率仍然很高，并且常常伴随着对传统化疗产生耐药性。因此，需要新的药物来治疗这些患者。近年来，我们对驱动CLL发病机制的生物学机制的理解有了显著提高，新的治疗策略也不断涌现。这篇综述总结了CLL生物学的最新见解，并描述了几种目前正在临床前研究和早期临床试验中探索的新药物和治疗策略。
